Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2012 – results from 1 January to 30 September, 2012

        Print
| Source: Veloxis Pharmaceuticals A/S
multilang-release

Investor service announcement no. 2/2012

  

To: NASDAQ OMX Copenhagen                                                    Hørsholm, Denmark, 9 November, 2012

 

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2012 – results from 1 January to 30 September, 2012

 

Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for the third Quarter 2012 on Wednesday 14 November, 2012 after 05:00 PM. Veloxis’ Management will host an accompanying conference call to discuss the financial results on Thursday 15 November, 2012 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York),

 

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)

+44 (0) 1452 555 131 (UK)

+1 866 682 8490 (USA)

Access code 64372811

 

Following the conference call, a recording will be available on the company’s website http://www.veloxis.com.

  

For more information, please contact:

 

John D. Weinberg                                      Johnny Stilou

EVP, Chief Commercial Officer                   EVP, Chief Financial Officer

Mobile: +1 908 302 3389                          Mobile: +45 21 227 227

Email: jdw@veloxis.com                           Email: jst@veloxis.com

  

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with a subsidiary in New Jersey. Veloxis is a speciality pharmaceutical company currently focused on the development of LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low‐scale up costs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit http://www.veloxis.com.